title: Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
abstract: The goal of this study was to examine the multiple-dose pharmacokinetics of selegiline and its metabolites desmethylselegiline, 1-methamphetamine, and 1-amphetamine after oral administration of selegiline HCl. Twelve healthy volunteers received 10 mg of selegiline HCl once daily for 8 days. The pharmacokinetic profiles of selegiline and the metabolites were examined from serum samples for 24 hours (i.e., the dosing interval, tau) on days 1, 4, and 8. The results indicated significant apparent accumulation of selegiline and desmethylselegiline during the 8-day period of selegiline administration. The AUC tau S of selegiline and desmethylselegiline were increased 2.7 fold (p < 0.001) and 1.5 fold (p < 0.001), respectively, from day 1 to day 8. However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short. Accordingly, the short half-lives of these compounds failed to predict the apparent accumulation. With both of the 1-amphetamine metabolites of selegiline, steady state was reached by day 4. We suggest that the most likely explanation for the apparent accumulation of selegiline and desmethylselegiline was the saturation of the MAO-B binding sites in tissues, although decreased first-pass metabolism of selegiline cannot be ruled out. The observed increase in selegiline and desmethylselegiline concentrations on multiple dosing is not likely to significantly increase the pharmacodynamic effect or adverse effects of selegiline compared with what has been found after a single 10-mg dose.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Laine
authors.forename: M
authors.initials: M
authors.lastname: Anttila
authors.forename: R
authors.initials: R
authors.lastname: Huupponen
authors.forename: O
authors.initials: O
authors.lastname: Mäki-Ikola
authors.forename: E
authors.initials: E
authors.lastname: Heinonen
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000661:Amphetamine / Q000097:blood / Q000493:pharmacokinetics; D000662:Amphetamines / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001665:Binding Sites; D000697:Central Nervous System Stimulants / Q000097:blood / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000097:blood / Q000493:pharmacokinetics; D008996:Monoamine Oxidase Inhibitors / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D012642:Selegiline / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D000662:Amphetamines; D000697:Central Nervous System Stimulants; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D008694:Methamphetamine; C017861:desmethylselegiline; D000661:Amphetamine